on SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech is recording significant growth in 2025
Sartorius Stedim Biotech reported solid performance for 2025, with preliminary unaudited revenue reaching €2,967 million, representing a 9.6% increase at constant exchange rates. Current EBITDA rose 17.3% to €914 million, resulting in a margin of 30.8%. Net income jumped 26.7% to €428 million.
This performance is primarily attributed to the growth in recurring consumables-related activities, while equipment sales showed signs of stabilization. All regions contributed to this growth, with a notable increase of 11.8% in the Americas region.
For 2026, the company expects growth of 6 to 10% at constant exchange rates, focusing more on innovation and customer needs.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SARTORIUS STED BIO news